Literature DB >> 22296786

Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice.

Ayman Al-Mariri1, Nermeen Haj Mahmoud, Razan Hammoud.   

Abstract

Brucella is gram-negative bacteria responsible for brucellosis in a wide variety of animals and humans. BALB/c mice were immunized with live Escherichia coli expression the p39 gene of Brucella melitensis, a gene coding for the periplasmic binding protein. Mice were injected with either E. coli BL21 (DE3) pEt15b or E. coli BL21 (DE3) pEt15b-p39 alone or adjuvanted with either CpG oligodeoxynucleotides (CpG ODN) or non-CpG ODN. E. coli BL21 (DE3) pEt15b-p39 with CpG ODN or with non-CpG ODN mice groups showed a significant IFN-γ production and T-cell proliferation as a reaction to P39 antigen. In addition, antibody responses (IgG, IgG1 and IgG2a), were only found in these two mice groups. A higher level of protection against B. melitensis 16M were observed in mice immunized with E. coli BL21 (DE3) pEt15b-p39 and CpG ODN comparing with those immunized with E. coli BL21 (DE3) pEt15b-p39 alone or with non-CpG ODN. No protection against B. melitensis 16M was observed in mice immunized with E. coli BL21 (DE3) pEt15b alone or with the adjuvant. Rev.1 protection at 4 and 8 weeks post-challenge was more effective than that observed with E. coli BL21 (DE3) pEt15b-p39 and CpG ODN. Copyright Â
© 2012 The International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22296786     DOI: 10.1016/j.biologicals.2012.01.002

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  6 in total

1.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

2.  Epitope-Based Vaccine of a Brucella abortus Putative Small RNA Target Induces Protection and Less Tissue Damage in Mice.

Authors:  Karen Cristina Oliveira; Gustavo Andrade Brancaglion; Natália C M Santos; Leonardo P Araújo; Evandro Novaes; Renato de Lima Santos; Sergio Costa Oliveira; Patrícia Paiva Corsetti; Leonardo Augusto de Almeida
Journal:  Front Immunol       Date:  2021-12-21       Impact factor: 7.561

Review 3.  Evaluation of Brucellosis Vaccines: A Comprehensive Review.

Authors:  Mohsen Heidary; Shirin Dashtbin; Roya Ghanavati; Marzie Mahdizade Ari; Narjess Bostanghadiri; Atieh Darbandi; Tahereh Navidifar; Malihe Talebi
Journal:  Front Vet Sci       Date:  2022-07-18

4.  Evaluation of immune responses to Brucella vaccines in mouse models: A systematic review.

Authors:  Atieh Darbandi; Shabnam Zeighamy Alamdary; Maryam Koupaei; Roya Ghanavati; Mohsen Heidary; Malihe Talebi
Journal:  Front Vet Sci       Date:  2022-09-02

5.  Screening of potential vaccine candidates against pathogenic Brucella spp. using compositive reverse vaccinology.

Authors:  Xiaodong Zai; Ying Yin; Fengyu Guo; Qiaoling Yang; Ruihua Li; Yaohui Li; Jun Zhang; Junjie Xu; Wei Chen
Journal:  Vet Res       Date:  2021-06-02       Impact factor: 3.683

Review 6.  Host-Brucella interactions and the Brucella genome as tools for subunit antigen discovery and immunization against brucellosis.

Authors:  Gabriel Gomez; Leslie G Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  Front Cell Infect Microbiol       Date:  2013-05-16       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.